PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of Votoplam
PTC Therapeutics reported positive topline results from the 24-month interim analysis of the PIVOT-HD extension study, showing a 52% slowing of disease progression at the 10 mg dose compared to a natural history cohort. Safety data remained favorable with no treatment-related neurofilament light chain protein increases observed at the 24-month mark for either dose level.
Key figures
- Drug Name
- Votoplam
- Phase Of Trial
- Phase 2 extension
- Slowing pct 5mg
- 28
- Slowing pct 10mg
- 52
- Phase3 enrollment count
- 770
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.